Cargando…
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
Metastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618524/ https://www.ncbi.nlm.nih.gov/pubmed/28858204 http://dx.doi.org/10.3390/ijms18091875 |
_version_ | 1783267206367281152 |
---|---|
author | Hoffman, Robert M. |
author_facet | Hoffman, Robert M. |
author_sort | Hoffman, Robert M. |
collection | PubMed |
description | Metastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model. |
format | Online Article Text |
id | pubmed-5618524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56185242017-09-30 Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † Hoffman, Robert M. Int J Mol Sci Review Metastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model. MDPI 2017-08-31 /pmc/articles/PMC5618524/ /pubmed/28858204 http://dx.doi.org/10.3390/ijms18091875 Text en © 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hoffman, Robert M. Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † |
title | Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † |
title_full | Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † |
title_fullStr | Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † |
title_full_unstemmed | Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † |
title_short | Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma † |
title_sort | patient-derived orthotopic xenograft (pdox) models of melanoma † |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618524/ https://www.ncbi.nlm.nih.gov/pubmed/28858204 http://dx.doi.org/10.3390/ijms18091875 |
work_keys_str_mv | AT hoffmanrobertm patientderivedorthotopicxenograftpdoxmodelsofmelanoma |